Literature DB >> 29457048

Farnesoid X Receptor Expression in Microscopic Colitis: A Potential Role in Disease Etiopathogenesis.

Joana Torres1, Carolina Palmela1, Pedro Gomes de Sena2, Maria Pia Costa Santos1, Catarina Gouveia1, Maria Helena Oliveira2, Ana Raquel Henriques3, Cecília Rodrigues4, Marília Cravo1, Paula Borralho1,5.   

Abstract

INTRODUCTION: Microscopic colitis (MC) is a chronic inflammatory bowel disease with unclear etiology. Bile acid (BA) malabsorption has been described in MC patients. Farnesoid X receptor (FXR) is the main BA receptor; FXR-mediated mechanisms prevent the noxious effects of BA accumulation, preserving the integrity of the intestinal epithelial barrier and preventing intestinal inflammation. AIM: Our aim was to describe the expression of FXR in patients with MC.
METHODS: Archival formalin-fixed paraffin-embedded samples from the terminal ileum, right and left colon were obtained from patients with MC and matched controls. Immunohistochemistry was performed and nuclear FXR expression scored in a semi-quantitative way.
RESULTS: 169 formalin-fixed paraffin-embedded samples from 35 patients with MC and 31 controls were retrieved. There was a significant reduction of FXR expression in patients with MC versus controls both in the right colon (moderate-strong FXR expression: 21.1 vs. 64.3%; p = 0.003) and left colon (moderate-strong FXR expression: 8.3 vs. 38.7%; p = 0.027). No significant differences in FXR expression were observed in the ileum of patients with MC (moderate-strong FXR expression: 76.9 vs. 90.9%; p = 0.5). We found no difference in FXR expression between the two types of MC. No association between the degree of lymphocyte infiltration or the thickness of collagen band and FXR expression was found.
CONCLUSIONS: Patients with MC present a significantly lower expression of FXR in the colon. This could render colonic epithelial cells more susceptible to the deleterious effects of BA, contributing to disease pathogenesis and symptoms in MC.

Entities:  

Keywords:  Bile salts; Farnesoid X receptor; Immunohistochemistry; Intestinal inflammation; Microscopic colitis

Year:  2017        PMID: 29457048      PMCID: PMC5806171          DOI: 10.1159/000481197

Source DB:  PubMed          Journal:  GE Port J Gastroenterol        ISSN: 2387-1954


  37 in total

1.  Distribution of collagenous colitis: utility of flexible sigmoidoscopy.

Authors:  M Tanaka; G Mazzoleni; R H Riddell
Journal:  Gut       Date:  1992-01       Impact factor: 23.059

2.  The Incidence of Microscopic Colitis: Microscopic No More.

Authors:  Nicole M Gentile; Eugene F Yen
Journal:  Dig Dis Sci       Date:  2017-06       Impact factor: 3.199

3.  Bile acid malabsorption in microscopic colitis and in previously unexplained functional chronic diarrhea.

Authors:  F Fernandez-Bañares; M Esteve; A Salas; T M Forné; J C Espinos; J Martín-Comin; J M Viver
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

Review 4.  Microscopic colitis: Current status, present and future challenges: statements of the European Microscopic Colitis Group.

Authors:  A Münch; D Aust; J Bohr; O Bonderup; F Fernández Bañares; H Hjortswang; A Madisch; L K Munck; M Ström; C Tysk; S Miehlke
Journal:  J Crohns Colitis       Date:  2012-06-15       Impact factor: 9.071

Review 5.  Review article: Microscopic colitis--lymphocytic, collagenous and 'mast cell' colitis.

Authors:  E F Yen; D S Pardi
Journal:  Aliment Pharmacol Ther       Date:  2011-05-04       Impact factor: 8.171

6.  Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease.

Authors:  Raffaella M Gadaleta; Karel J van Erpecum; Bas Oldenburg; Ellen C L Willemsen; Willem Renooij; Stefania Murzilli; Leo W J Klomp; Peter D Siersema; Marguerite E I Schipper; Silvio Danese; Giuseppe Penna; Gilles Laverny; Luciano Adorini; Antonio Moschetta; Saskia W C van Mil
Journal:  Gut       Date:  2011-01-17       Impact factor: 23.059

7.  Incidence, Clinical Presentation, and Associated Factors of Microscopic Colitis in Northern France: A Population-Based Study.

Authors:  Mathurin Fumery; Mathieu Kohut; Corinne Gower-Rousseau; Alain Duhamel; Franck Brazier; Francoise Thelu; Francis Nagorniewicz; Francois Lamarche; Eric Nguyen-Khac; Charles Sabbagh; Julien Loreau; Jean-Frederic Colombel; Guillaume Savoye; Denis Chatelain; Jean-Louis Dupas
Journal:  Dig Dis Sci       Date:  2016-09-22       Impact factor: 3.199

8.  Increased transmucosal uptake of E. coli K12 in collagenous colitis persists after budesonide treatment.

Authors:  Andreas Münch; Johan D Söderholm; Ake Ost; Magnus Ström
Journal:  Am J Gastroenterol       Date:  2009-02-10       Impact factor: 10.864

9.  Bile acid malabsorption in children and adolescents with chronic colitis.

Authors:  L Holmquist; H Andersson; N Rudic; C Ahrén; S P Fällström
Journal:  Scand J Gastroenterol       Date:  1986-01       Impact factor: 2.423

10.  Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease.

Authors:  Rian M Nijmeijer; Raffaella M Gadaleta; Saskia W C van Mil; Adriaan A van Bodegraven; J Bart A Crusius; Gerard Dijkstra; Daan W Hommes; Dirk J de Jong; Pieter C F Stokkers; Hein W Verspaget; Rinse K Weersma; C Janneke van der Woude; Janneke M Stapelbroek; Marguerite E I Schipper; Cisca Wijmenga; Karel J van Erpecum; Bas Oldenburg
Journal:  PLoS One       Date:  2011-08-22       Impact factor: 3.240

View more
  6 in total

Review 1.  Diagnosis and Management of Microscopic Colitis in Pediatric Patients.

Authors:  Salina Khushal; Maria Oliva-Hemker
Journal:  Paediatr Drugs       Date:  2022-05-02       Impact factor: 3.022

Review 2.  Microscopic colitis.

Authors:  Kristin E Burke; Mauro D'Amato; Siew C Ng; Darrell S Pardi; Jonas F Ludvigsson; Hamed Khalili
Journal:  Nat Rev Dis Primers       Date:  2021-06-10       Impact factor: 52.329

3.  Fecal Microbiota of Diarrhea-Predominant Irritable Bowel Syndrome Patients Causes Hepatic Inflammation of Germ-Free Rats and Berberine Reverses It Partially.

Authors:  Qiong Jia; Lu Zhang; Jindong Zhang; Fei Pei; Shiwei Zhu; Qinghua Sun; Liping Duan
Journal:  Biomed Res Int       Date:  2019-04-03       Impact factor: 3.411

Review 4.  The Pathophysiology of Farnesoid X Receptor (FXR) in the GI Tract: Inflammation, Barrier Function and Innate Immunity.

Authors:  Kemp M Anderson; Christopher P Gayer
Journal:  Cells       Date:  2021-11-17       Impact factor: 6.600

5.  European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations.

Authors:  Stephan Miehlke; Danila Guagnozzi; Yamile Zabana; Gian E Tontini; Anne-Marie Kanstrup Fiehn; Signe Wildt; Johan Bohr; Ole Bonderup; Gerd Bouma; Mauro D'Amato; Peter J Heiberg Engel; Fernando Fernandez-Banares; Gilles Macaigne; Henrik Hjortswang; Elisabeth Hultgren-Hörnquist; Anastasios Koulaouzidis; Jouzas Kupcinskas; Stefania Landolfi; Giovanni Latella; Alfredo Lucendo; Ivan Lyutakov; Ahmed Madisch; Fernando Magro; Wojciech Marlicz; Emese Mihaly; Lars K Munck; Ann-Elisabeth Ostvik; Árpád V Patai; Plamen Penchev; Karolina Skonieczna-Żydecka; Bas Verhaegh; Andreas Münch
Journal:  United European Gastroenterol J       Date:  2021-02-22       Impact factor: 4.623

6.  Hormonally Regulated Myogenic miR-486 Influences Sex-specific Differences in Cancer-induced Skeletal Muscle Defects.

Authors:  Ruizhong Wang; Poornima Bhat-Nakshatri; Xiaoling Zhong; Teresa Zimmers; Harikrishna Nakshatri
Journal:  Endocrinology       Date:  2021-10-01       Impact factor: 5.051

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.